> Skip repeated content
photo of David R. Fernandez, MD, PhD

David R. Fernandez, MD, PhD


About Dr. Fernandez


Profile Video


Specialized Centers

Special Expertise

Polymyositis Inclusion
Body Myositis
Systemic Lupus Erythematosus

Patient Stories

Patient ratings for Dr. Fernandez


Learn more about our patient ratings.


Please call our office if you have questions regarding your insurance coverage. If you have out of network benefits, then your insurance may reimburse you for a portion of your office visit. We will work with you and your insurance to minimize your out-of-pocket costs. Financial assistance may be available for patients in need.



Assistant Attending Physician, Hospital for Special Surgery


American Board of Internal Medicine - Internal Medicine
American Board of Internal Medicine - Rheumatology


Lupus and Antiphospholipid Syndrome Center of Excellence Research Fund Award, 2016
F31 Predoctoral Fellowship, NIAMS, 2008-201


SUNY Upstate Medical University, Syracuse


NewYork-Presbyterian - Weill Cornell Medical Center, New York


NewYork-Presbyterian - Weill Cornell Medical Center, New York


Hospital for Special Surgery, New York

State Licensure


English, Spanish

Publications by Dr. Fernandez

Patient Education

Professional Education

Blog Posts

Selected Journal Articles

Fernandez D, Kirou KA. What Causes Lupus Flares? (2016) Current Rheumatology Reports. 18(3):14. doi: 1007/s11926-016-0562-3.

Fernandez DR, Markenson JA. Gout and Hyperuricemia – Serious Risk Factors for Morbidity and Mortality or Just Indicator "The Good Life" – The Evidence to Date. (2015) Current Treatment Options in Rheumatology. 1(2):167-181.

Caza TN, Fernandez DR, Talaber G, Oaks Z, Haas M, Madaio MP, Lai ZW, Miklossy G, Singh RR, Chudakov DM, Malomi W,Banki K, Perl A. HRES-1/Rab4-mediated depletion of Drp1 impairs mitochondrial homeostasis and represents a target for treatment of SLE. (2014) Annals of the Rheumatic Diseases. 73(10):1888-97. (PMCID: PMC4047212)

Fernandez D, Perl A. mTOR signaling: a central pathway to pathogenesis in systemic lupus erythematosus? (2010) Discovery Medicine. 9(46):173-8. (PMCID: PMC4047522)

Hanczko R, Fernandez DR, Doherty E, Qian Y Vas G, Niland B, Telarico T, Garba A, Banerjee S, Middleton FA, Barrett D,Barcza M, Banki K, Landas SK, Perl A. Prevention of hepatocarcinogenesis and increased susceptibility to acetaminophen-induced liver failure in transaldolase-deficient mice by N-acetylcysteine. (2009) Journal of Clinical Investigation. 119(6):1546-57. (PMCID: PMC2689120)

Fernandez DR, Telarico T, Bonilla E, Li Q, Banerjee S, Middleton FA, Phillips PE, Crow MK, Oess S, Muller-Esterl W, Perl A. Activation of mammalian target of rapamycin controls the loss of TCRζ in lupus T cells through HRES-1/Rab4-regulated lysosomal degradation. (2009) Journal of Immunology. 182(4):2063-73. (PMCID: PMC2676112)

Perl A, Fernandez DR, Telarico T, Doherty E, Francis L, Phillips PE. T-cell and B-cell signaling biomarkers and treatment targets in lupus. (2009) Current Opinions in Rheumatology. 21(5):454-464.

Fernandez D, Bonilla E, Phillips P, Perl A. Signaling Abnormalities in Systemic Lupus Erythematosus as Potential Drug Targets. (2006) Endocrine, Metabolic & Immune Disorders – Drug Targets. 6(4):305-311.

Fernandez D, Bonilla E, Mirza N, Niland B, Perl A. Rapamycin reduces disease activity and normalizes T cell activation-induced calcium fluxing in patients with systemic lupus erythematosus. (2006) Arthritis & Rheumatism. 54(9):2983-8. (PMCID:PMC4034146)

For more publications, please see the PubMed listing.


Research Interests

Currently studying the role of cell-free mitochondrial DNA in triggering interferon production and disease flares in patients with systemic lupus erythematosus, as well as the effect of medications used to treat lupus patients on mitochondrial DNA release.

Additionally, working to identify clinical features in a large cohort of lupus patients that may allow us to better define subgroups of patients.

Patient Registries

Industry Relationships

Industry Relationships

One of the goals of HSS is to advance the science of orthopedic surgery, rheumatology, and related disciplines for the benefit of patients. Physicians at HSS may collaborate with outside companies for education, research and medical advances. HSS supports this collaboration in order to foster medical breakthroughs; however HSS also believes that these collaborations must be disclosed.

As part of the disclosure process, this website lists physician collaborations with outside companies. The disclosures are provided by information provided by the physician and other sources and are updated regularly. Further information may be available on individual company websites.

Below are the healthcare industry relationships reported by Dr. Fernandez as of December 05, 2019.

  • Bristol Myers Squibb - Research Support
  • Corbus Pharmaceuticals - Research Support
  • Medpage Today - Editor
  • Northwell Health - Research Support

By disclosing the collaborations of HSS physicians with industry on this website, HSS and its physicians make this information available to their patients and the public, thus creating a transparent environment for those who are interested in this information. Further, the HSS Conflicts of Interest Policy does not permit physicians to collect royalties on products developed by him/her that are used on patients at HSS.

Patients should feel free to ask their HSS physicians questions about these relationships.

Dr. Fernandez in the News